OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Sznol on Managing Patients Beyond Initial Treatment in Melanoma

January 3rd 2020

Mario Sznol, MD, discusses the management of patients with melanoma who progress on immune checkpoint inhibitors.

Experts Provide Insight on the Biggest Advances in Oncology in 2019

January 1st 2020

OncLive interviewed experts at the State of the Science Summits™ in December 2019 on what the biggest advances in oncology were in 2019.

Dr. Emens on the Future of Immunotherapy in Ovarian Cancer

December 23rd 2019

Leisha A. Emens, MD, PhD, discusses a potential future with immunotherapy in ovarian cancer.

Dr. Rizk on the Role of Surgery in Nonmetastatic Lung Cancer

December 23rd 2019

Nabil P. Rizk, MD, MS, MPH, discusses the role of anatomic surgical resection in nonmetastatic lung cancer.

Dr. Olin on the Utility of Venetoclax in AML

December 23rd 2019

Rebecca L. Olin, MD, MSCE, associate professor, Department of Medicine (Hematology/Oncology), University of California San Francisco, discusses the utility of venetoclax in acute myeloid leukemia.

Dr. Levy on Treatments for Oncogenic-Driven NSCLC

December 21st 2019

Benjamin P. Levy, MD, discusses treatment options for patients with oncogenic-driven non–small cell lung cancer.

Dr. Crafton on the Impact of PARP Inhibitors in Recurrent Ovarian Cancer

December 21st 2019

Sarah Crafton, MD, discusses the impact of PARP inhibitors on patients with recurrent ovarian cancer.

Dr. Fakhri on Ibrutinib-Containing Regimens in CLL

December 21st 2019

Bita Fakhri, MD, MPH, discusses the trials that led to ibrutinib-containing regimens becoming the standard of care for chronic lymphocytic leukemia over traditional chemotherapy options.

Dr. Traina on the FDA Approval of Trastuzumab Deruxtecan for HER2+ Breast Cancer

December 21st 2019

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201) for patients with HER2-positive, locally advanced, or metastatic breast cancer who have been treated with trastuzumab (Herceptin) and pertuzumab (Perjeta) and have disease progression after ado-trastuzumab emtansine (T-DM1; Kadcyla).

Dr. Gralow on the Global Impact of Biosimilars

December 20th 2019

Julie R. Gralow, MD, clinical director, Breast Medical Oncology, Seattle Cancer Care Alliance, professor, medical oncology, University of Washington School of Medicine, discusses the global impact of biosimilars in HER2-positive breast cancer.

Dr. Vulfovich on Broad Molecular Profiling in mCRC

December 20th 2019

Michel Vulfovich, MD, medical director, Sickle Cell Disease and Gynecology Oncology programs, Memorial Healthcare System, discusses the utility of broad molecular profiling in metastatic colorectal cancer (mCRC).

Dr. Davids on Cost Effectiveness of Time-Limited Therapy With Venetoclax/Obinutuzumab in CLL

December 20th 2019

Matthew S. Davids, MD, MMSc, associate director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses the potential cost effectiveness of a 12-month fixed duration of venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) in first-line chronic lymphocytic leukemia (CLL).

Dr. Mato on the CLL14 Trial Results in CLL

December 19th 2019

Anthony R. Mato, MD, MSCE, discusses the phase III CLL14 trial in patients with previously untreated chronic lymphocytic leukemia.

Dr. O'Regan on Biosimilar Education in Breast Cancer

December 19th 2019

Ruth O’Regan, MD, discusses patient education as biosimilars are implemented into practice for breast cancer.

Dr. Hellmann on Sentinel Lymph Node Mapping in Endometrial Cancer

December 19th 2019

Mira Hellmann, MD, gynecologic oncologist and assistant professor, John Theurer Cancer Center, Hackensack University Medical Center, discusses the use of sentinel lymph node mapping in patients with endometrial cancer.

Dr. Brufsky on Trastuzumab Biosimilars in Breast Cancer

December 19th 2019

Adam M. Brufsky, MD, PhD, discusses the utility of trastuzumab biosimilars in breast cancer.

Dr. Hart on Antibody-Drug Conjugates in HER2+ Breast Cancer

December 19th 2019

Lowell L. Hart, MD, FACP, discusses the utility of antibody-drug conjugates in HER2-positive breast cancer.

Dr. Klebanoff on Biosimilars Reducing Financial Toxicity in Breast Cancer

December 19th 2019

Christopher A. Klebanoff, MD, discusses using biosimilars to reduce financial toxicity in breast cancer.

Dr. O'Malley on Ongoing Clinical Trials Evaluating Immunotherapy in Ovarian Cancer

December 19th 2019

David O’Malley, MD, discusses ongoing clinical trials evaluating immunotherapy in patients with advanced ovarian cancer.

Dr. Molena on Lung-Sparing Surgery in Early-Stage Lung Cancer

December 19th 2019

Daniela Molena, MD, director, Esophageal Surgery Program, Memorial Sloan Kettering Cancer Center, discusses the use of lung-sparing surgery in early-stage lung cancer.